PCRX Stock News 76.25 05/13/2014 18:42:40 Pacira Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pacira Pharmaceuticals (PCRX) 76.25 $PCRX

Insider Trading Alert - ENS, HOS And PCRX Traded By Insiders
at The Street - Tue May 13, 10:45AM CDT
Stocks with insider trader activity include ENS, HOS and PCRX

Use Options For A Chance To Buy PCRX At A 25% Discount
at The Street - Fri May 09, 10:44AM CDT
Looking back to 31 days ago, Pacira Pharmaceuticals priced a 1,600,000 share secondary stock offering at $64.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...

Insider Trading Alert - BLL, PCRX And TIBX Traded By Insiders
at The Street - Thu May 08, 11:07AM CDT
Stocks with insider trader activity include BLL, PCRX and TIBX

Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
Business Wire - Wed May 07, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL(R) (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAREL in femoral nerve block for total knee arthroplasty, and will also include additional safety data from a Phase 3 study of EXPAREL used to perform an intercostal nerve block for thoracotomy.

Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:30AM CDT
Shares of Pacira Pharma (PCRX) have been rising since the company reported first quarter results

Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.

'Fast Money' Recap: Financial Sector Follies
at The Street - Tue May 06, 4:00AM CDT
The trading panel discussed which stocks have done well and which have not.

Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Mon May 05, 2:30PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 8 a.m. PT in Las Vegas. Mr. Stack is expected to present an overview of the company.

Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
Business Wire - Thu May 01, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2014.

Frost & Sullivan Research Reveals Clinical and Economic Advantages of ON-Q* over Bupivacaine Liposome Injectable Suspension
PR Newswire - Wed Apr 30, 8:00AM CDT
I-Flow LLC, a Kimberly-Clark Health Care Company and manufacturer of the ON-Q Pain Relief System (ON-Q), today announced the full findings of a Frost & Sullivan white paper documenting clinician perspective that ON-Q delivers superior pain control over the full length of the postoperative period and at a lower cost compared to Bupivacaine Liposome Injectable Suspension.

Pacira Pharmaceuticals (PCRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:57AM CDT
Pacira Pharmaceuticals is actually looking pretty good on its own too. The firms prospects looks good in both the short and long term.

Early Briefing on Pharma Equities -- Research on TherapeuticsMD, Pacira Pharma, GW Pharma, and Depomed
PR Newswire - Mon Apr 21, 10:00AM CDT
The trading session on Thursday, April 17, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,408.54, down 0.10% and the NASDAQ Composite closed at 4,095.52, up 0.23%. The S&P 500 finished the session 0.14% higher at 1,864.85. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day flat at 658.58, while it has edged lower by 0.30% in previous three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), GW Pharmaceuticals PLC (NASDAQ: GWPH) and Depomed Inc. (NASDAQ: DEPO). Free technical research on TXMD, PCRX, GWPH and DEPO can be downloaded upon signing up at:

Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
Business Wire - Thu Apr 17, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call and providing the Conference ID 2786177.

Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global

Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Apr 15, 3:40PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4).

Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free

Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.

Nasdaq stocks posting largest percentage increases
AP - Wed Apr 09, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 220

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 263

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 82

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 118

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 26

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 8

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 26

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 86

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 68

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading

Top 5 Most Recently Viewed Articles

Michael Baker International Enhances Pavement Management Strategies

Updated Category News Views 313

Michael Baker International Teams Up with CVAG Michael Baker International, a well-known leader in engineering and consulting services, has recently been selected by the Coachella Valley Association of Governments (CVAG) for an important project focused on improving the area's pavement condition assessments. This partnership marks a significant step toward enhancing the...

Continue Reading
Fidus Investment Corporation Announces $100 Million Note Offering

Updated Category News Views 307

Fidus Investment Corporation's Recent Offering Announcement Fidus Investment Corporation (NASDAQ: FDUS) has recently made a significant announcement regarding its financial strategy. The company has priced an underwritten public offering of 6.750% notes, with an aggregate principal amount of $100 million, due in 2030. This initiative is aimed at strengthening its capital...

Continue Reading
WillScot Strengthens Board with New Appointment to Drive Growth

Updated Category News Views 49

WillScot Appoints Worthing Jackman to Board of Directors WillScot Holdings Corporation (NASDAQ: WSC), a leader in flexible space and storage solutions, has made a strategic move by appointing Worthing Jackman to its Board of Directors. This significant addition is aimed at reinforcing the company's growth strategy and bolstering its financial and operational performance....

Continue Reading
National Press Club Reacts to Pentagon's New Media Restrictions

Updated Category News Views 510

Concerns Regarding Pentagon's Media Access Restrictions Recently, the National Press Club leadership voiced significant concerns about new media restrictions imposed by the Pentagon. A statement from the club highlighted that these restrictions threaten transparency and reduce public access to information critical for accountability. Impact on Journalistic Integrity...

Continue Reading
Dogecoin and Shiba Inu Surge: A New Era for Meme Coins

Updated Category News Views 100

A Look at the Recent Surge in Dogecoin and Shiba Inu Recently, Dogecoin and Shiba Inu, both leaders in the meme coin market, have experienced notable price spikes. Dogecoin's value has risen by 4.5%, while Shiba Inu has jumped an impressive 8%. These increases follow important economic news about a cut in interest rates, which is bringing renewed optimism among crypto...

Continue Reading